FibroBiologics Inc. (NASDAQ:FBLG) Stock Now Rated “Reduce” by Wall Street Analysts

by · The Markets Daily

Shares of FibroBiologics Inc. (NASDAQ:FBLG – Get Free Report) have been assigned an average recommendation of “Reduce” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $73.00.

Several brokerages have recently commented on FBLG. Weiss Ratings upgraded FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, September 4th. HC Wainwright reiterated a “buy” rating and set a $6.00 target price (down from $8.00) on shares of FibroBiologics in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft downgraded shares of FibroBiologics to an “underperform” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen upgraded shares of FibroBiologics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th.

View Our Latest Stock Analysis on FBLG

FibroBiologics Price Performance

Shares of NASDAQ:FBLG opened at $1.39 on Wednesday. The business’s 50 day moving average is $1.24 and its 200 day moving average is $1.60. The stock has a market cap of $9.26 million, a P/E ratio of -0.27 and a beta of 1.65. FibroBiologics has a 52-week low of $0.62 and a 52-week high of $12.40.

FibroBiologics (NASDAQ:FBLG – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.27. On average, sell-side analysts anticipate that FibroBiologics will post -3 EPS for the current fiscal year.

FibroBiologics Company Profile

(Get Free Report)

FibroBiologics, Inc is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. The company’s research focuses on fibroblasts, a type of cell involved in tissue maintenance and repair, and the biologically active factors and extracellular vesicles that these cells produce.

FibroBiologics is developing a proprietary platform intended to generate therapeutic products from fibroblast-derived cells and their secretions. Its pipeline is aimed at conditions associated with tissue damage, inflammation, and impaired regeneration, including multiple sclerosis, psoriasis, and degenerative disc disease.

Featured Stories